SINGAPORE, Oct. 15, 2025 /PRNewswire/ — What if cancer care could move from reactive to proactive? At the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025),
Panel discussion: Ida Deleskog Lindstroem, Global Medical Affairs Director, Gene Solutions (first from left), Dr. Christopher Wong, Chief Operations Officer/Laboratory Director, Gene Solutions (second from left), Dr. Lee Chern Siang, Raffles Cancer Centre (second from right), and Assistant Professor Dr. Tan Chia-Ken Aaron, NCCS (first from right), discussing multi-omics and ctDNA-MRD advancements.
Gene Solutions’ Scientific Approach
Unlike single-modality tests, Gene Solutions’ platform integrates DNA, RNA, and AI-enhanced multi-omics signals for comprehensive tumor profiling and personalized ctDNA monitoring. This multi-omics approach has the potential to improve ctDNA sensitivity, detect complex gene fusions, and predict primary tumor locations – supporting deeper insights for more informed, personalized treatment decisions.
Recent studies published in JCO Oncology Advances1 and Nature’s npj Breast Cancer2 highlight the potential of ctDNA-based MRD testing to predict early recurrence and contribute to affordable monitoring strategies in real-world contexts. Through its CAP-accredited Singapore laboratory and global operations network, Gene Solutions fosters scientific collaboration to advance genomic research and precision oncology across the Asia-Pacific.
A Call for Collaboration
Ida Deleskog Lindstroem, Global Medical Affairs Director, emphasized: “Molecular residual disease (MRD) and multi-omics platforms show promise in advancing precision oncology by enabling clinicians to detect cancer recurrence earlier and tailor treatments more effectively. We invite oncologists, researchers, and healthcare partners across Asia-Pacific to collaborate in advancing these technologies, fostering data-driven, personalized care that aims to improve patient outcomes across diverse healthcare systems.”
Read more about symposium highlight at: https://genesolutions.com/news/gene-solutions-showcases-mrd-and-multi-omics-advances-at-sso-asm-2025-in-singapore
About Gene Solutions
Gene Solutions is a multinational biotechnology company at the forefront of genetic testing and research innovation across the Asia-Pacific region. Leveraging Next-Generation Sequencing (NGS) and Artificial Intelligence, the company offers a comprehensive portfolio of advanced solutions, including:
- Next-generation non-invasive prenatal testing (NIPT) for fetal and maternal health.
- Multi-cancer screening using clinically validated multi-omics circulating tumor DNA (ctDNA) technology for early detection and tumor-of-origin localization.
- Comprehensive genomic and transcriptomic profiling combined with ctDNA-based molecular residual disease (MRD) monitoring to guide precision treatment and track disease progression.
With over two million genetic tests delivered, Gene Solutions is recognized for its proprietary research, CAP-accredited laboratories, and contributions to advancing precision medicine through clinical studies, technology development, and regional collaborations.
|
Disclaimer: For healthcare professionals and researchers only. Not intended as medical advice. Claims based on published studies; ctDNA-MRD and multi-omics approaches requires further clinical validation.
|
References
(1) Hoang, V.-A.N. et al. (2025) ‘Real-World utilization and performance of circulating tumor DNA monitoring to predict recurrence in solid tumors,’ JCO Oncology Advances, Volume 2. DOI: 10.1200/OA-24-00084
(2) Nguyen, S. T., Nguyen Hoang, V. A., Nguyen Trieu, V., et al. Personalized mutation tracking in circulating-tumor DNA predicts recurrence in patients with high-risk early breast cancer. npj Breast Cancer 11, 58 (2025). DOI: 10.1038/s41523-025-00778-z
